ESC 2026: AstraZeneca’s oral relaxin agonist succeeds in Phase II trial

The win marks a milestone, given previous terminations in this drug class from AstraZeneca and Eli Lilly. The win marks a milestone, given previous terminations in this drug class from AstraZeneca and Eli Lilly. AstraZeneca announced the Phase IIb data at ESC 2026. Credit: Mats Wiklund AstraZeneca’s oral relaxin agonist improved cardiac function in patients with chronic heart failure in a Phase IIb trial. In data from the LUMINERA trial (NCT06299826) presented at the European Society of Cardiology (ESC 2026) meeting, which took place in Munich, Germany from 28 to 31 August, three doses of AZD5462 were pitted against placebo…

Source: Clinical Trials Arena